News

Scholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drug
Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...
Opinion
Dow Jones Top Company Headlines at 7 AM ET: It's Time for UnitedHealth to Get Transparent With Its Accounting. But Will It? | The ...
Streaming Finally Outpaces Traditional TV. The Leading Platform Might Surprise You. YouTube represented 12.5% of all television viewing in May-the highest share of TV for any streamer to date. The new ...
Scholar Rock's drug helps patients on Zepbound preserve muscle in trial
Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...